Journal article
Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]
Abstract
BackgroundAlthough serotonin reuptake inhibitors are effective in the treatment of OCD, many patients fail to respond to these agents. Growing evidence from open-label and placebo-controlled trials suggests a role for augmentation of SRIs with atypical antipsychotics in OCD. Quetiapine is generally well tolerated and previous open-label data has produced mixed results in OCD and additional controlled data is needed.MethodsWe undertook a …
Authors
Carey PD; Vythilingum B; Seedat S; Muller JE; van Ameringen M; Stein DJ
Journal
BMC Psychiatry, Vol. 5, No. 1,
Publisher
Springer Nature
DOI
10.1186/1471-244x-5-5
ISSN
1471-244X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAntipsychotic AgentsDibenzothiazepinesDouble-Blind MethodDrug Administration ScheduleDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPlacebosPsychiatric Status Rating ScalesQuetiapine FumarateSelective Serotonin Reuptake InhibitorsTreatment FailureTreatment Outcome